Crown Bioscience Expands Services in Europe to Meet Oncology and Diabetes Research Demand
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Crown Bioscience, a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research, has tripled the size of its team in Europe to meet demand for its services.
“Our expanded staff, combined with the breadth and depth of our in vitro and in vivo models and our ability to quantify the efficacy and pharmacological profile of compounds, help our clients quickly advance the most promising candidates.”
“As the only truly global provider of translational services for oncology and diabetes with support services and facilities in Europe, the Americas and Asia, we continue to respond to our clients’ growing research needs by strengthening our team in Europe and Israel,” said Laurie Heilmann, senior vice president of global strategy, marketing and business development at Crown Bioscience.
Crown Bioscience’s new director of business development, Keith Payne, will have specific responsibility for the increasing number of clients in Israel. Payne has worked in the pharmaceutical industry in technical and commercial functions for more than 25 years.
A chartered biologist with a strong background in bench research, Jonny McMichael, Ph.D., is Crown Bioscience’s new director of business development. McMichael has more than 15 years of experience in various business development, general management and scientific roles at companies involved in drug discovery and preclinical services. His responsibilities include business development in Scotland, the Cambridge area in the UK, and the Nordic region.
They join other industry veterans that Crown Bioscience recently added to its European team including Sebastian Dempe, Ph.D., manager of business development for central Europe; and Severine Marrony, Ph.D., manager of business development in France.
“We have assembled a first-class team in Europe who have a great deal of experience and dedication,” said Heilmann. “Our expanded staff, combined with the breadth and depth of our in vitro and in vivo models and our ability to quantify the efficacy and pharmacological profile of compounds, help our clients quickly advance the most promising candidates.”
For more information about how Crown Bioscience works to help researchers improve patient outcomes, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.
October 08, 2015
Source: http://www.businesswire.com/
